JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1988; 12:1334-1341
© 1988 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kishimoto, C
Right arrow Articles by Abelmann, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kishimoto, C
Right arrow Articles by Abelmann, W.

Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets

C Kishimoto, CS Crumpacker, and WH Abelmann

Charles A. Dana Research Institute, Beth Israel Hospital, Boston, Massachusetts 02215.

The efficacy of the synthetic nucleoside ribavirin in the therapy of experimental myocarditis caused by coxsackievirus B3 and its effects on peripheral and splenic lymphocyte subsets were investigated. Two week old male C3H/He mice were inoculated with coxsackievirus B3. Ribavirin was administered subcutaneously on days 0 to 15 (experiment I) and on days 4 to 15 (experiment II) in a dose of 200 (experiment I: Group 2, n = 10; experiment II: Group 5, n = 10) or 400 mg/kg per day (experiment I: Group 3, n = 10; experiment II: Group 6, n = 10). Control mice (experiment I: Group 1, n = 15; experiment II: Group 4, n = 14) received an injection of saline solution. In experiment I, mice treated with ribavirin survived significantly longer than did control mice (p = 0.005, Group 1 versus Group 2; p = 0.001, Group 1 versus Group 3). In experiment II, the survival rate on day 15 in ribavirin-treated mice was high compared with that in control mice (Group 4 = 14.3%, Group 5 = 20%, Group 6 = 50%). Myocardial viral titers on days 5 to 8 were significantly lower in ribavirin-treated mice of both experiments than in control mice.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
J K S Chia
The role of enterovirus in chronic fatigue syndrome
J. Clin. Pathol., November 1, 2005; 58(11): 1126 - 1132.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. P. Liu and J. W. Mason
Advances in the Understanding of Myocarditis
Circulation, August 28, 2001; 104(9): 1076 - 1082.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. C. Lenzo, G. R. Shellam, and C. M. Lawson
Ganciclovir and Cidofovir Treatment of Cytomegalovirus-Induced Myocarditis in Mice
Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1444 - 1449.
[Abstract] [Full Text]

Home page
 CirculationHome page
J. Fohlman, K. Pauksen, T. Hyypia, G. Eggertsen, A. Ehrnst, N.G. Ilback, and G. Friman
Antiviral Treatment With WIN 54 954 Reduces Mortality in Murine Coxsackievirus B3 Myocarditis
Circulation, November 1, 1996; 94(9): 2254 - 2259.
[Abstract] [Full Text]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1988 by the American College of Cardiology Foundation.